Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus exemestane in HR-positive, HER2-negative advanced breast cancer
ChiCTR2100053788Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat and exemestane in breast cancer, sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Progression-free survival. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
tucidinostatexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100053788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053788.